Nivolumab plus ipilimumab in metastatic uveal melanoma: a real-life, retrospective cohort of 47 patients

Although combined PD-1/CTLA-4 inhibition showed limited efficacy in single-arm, phase II trials in metastatic uveal melanoma (mUM), such combination appears frequently used in mUM patients. We here report our experience with nivolumab/ipilimumab in mUM. A retrospective cohort of 47 mUM patients, 24...

Descripción completa

Detalles Bibliográficos
Autores principales: Salaün, Hélène, de Koning, Leanne, Saint-Ghislain, Mathilde, Servois, Vincent, Ramtohul, Toulsie, Garcia, Agathe, Matet, Alexandre, Cassoux, Nathalie, Mariani, Pascale, Piperno-Neumann, Sophie, Rodrigues, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450894/
https://www.ncbi.nlm.nih.gov/pubmed/36092639
http://dx.doi.org/10.1080/2162402X.2022.2116845

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450894/
https://www.ncbi.nlm.nih.gov/pubmed/36092639
http://dx.doi.org/10.1080/2162402X.2022.2116845

Ejemplares similares